Benitec Biopharma (BNTC)
(Delayed Data from NSDQ)
$9.47 USD
-0.02 (-0.21%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $9.47 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BNTC 9.47 -0.02(-0.21%)
Will BNTC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BNTC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BNTC
Piper Sandler starts Benitec at overweight, cites BB-301 opportunity
Benitec Biopharma initiated with bullish view at Piper Sandler, here's why
Buy Rating on Benitec Biopharma: Promising Prospects for OPMD Treatment with BB-301
CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements
Buy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid Financials